905 reports of this reaction
2.2% of all OSIMERTINIB reports
#5 most reported adverse reaction
FATIGUE is the #5 most commonly reported adverse reaction for OSIMERTINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 905 FDA adverse event reports linking OSIMERTINIB to FATIGUE. This represents approximately 2.2% of all 41,863 adverse event reports for this drug.
OSIMERTINIB has an overall safety score of 93 out of 100. Patients taking OSIMERTINIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for OSIMERTINIB, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for OSIMERTINIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 905 FDA reports for OSIMERTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.2% of all adverse event reports for OSIMERTINIB, making it a notable side effect.
If you experience fatigue while taking OSIMERTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.